Background. Stavudine is widely used in developing countries. Lipoatrophy and mitochondrial toxicity have been linked to stavudine use, but it is unclear whether switching to a lower dose can reduce these toxicities while maintaining human immunodeficiency virus (HIV) suppression.
merase-g have led to modest improvements in limb fat, mtDNA levels, and adipocyte apoptosis [6] [7] [8] [9] [10] . In developed countries, most subjects with lipoatrophy have substituted stavudine with less-toxic NRTIs; however, this may not be feasible in developing countries.
A recent systematic review of 9 clinical trials examining stavudine use demonstrated that a dosage of 30 mg twice daily has efficacy equivalent to that of the 40-mg dose prescribed to adults weighing 160 kg, with fewer adverse effects [11] . One trial changed treatments for subjects receiving stavudine at 40 mg twice daily to either receiving tenofovir or stavudine at 30 mg twice daily; no changes in PBMC mtDNA or lactate levels were found [12] .
The current stavudine label suggests dosage reduction to 20 mg twice daily for patients who develop peripheral neuropathy while receiving 40 mg twice daily (or 15 mg twice daily for those receiving 30 mg twice daily). However, clinical experience with the use of stavudine at 20 mg twice daily outside of patients with neuropathy is lacking, and it is unclear whether administration of lower-dose stavudine (20 mg for those у60 kg; 15 mg for those !60 kg) would allow continued virological suppression with fewer mitochondrial toxicities. Thus, we investigated the effect of reducing the stavudine dose on metabolic parameters in subjects treated with stavudine-based antiretroviral therapy.
METHODS

Population and study design.
This was an open-labeled, randomized, controlled study. HIV-infected subjects (age, у18 years) were recruited in the Special Immunology Unit of University Hospitals of Cleveland (Cleveland, OH) and in the MacGregor Infectious Diseases Clinic of the Hospital of the University of Pennsylvania (Philadelphia, PA). Inclusion criteria required HIV-infected patients with stable antiretroviral therapy containing standard doses of stavudine for у24 weeks, and an HIV-1 RNA level of !50 copies/mL (or branched DNA level of !75 copies/mL). Also, patients had to have at least 1 of the following markers or risk factors for mitochondrial toxicity: (1) self-reported lipoatrophy, defined as fat loss in the face, extremities, and/or buttocks, and confirmed by the investigator; (2) 2 consecutive elevated lactate measurements; (3) regular excessive use of alcohol within the past year, defined as alcohol intake of 140 g per day for men (or 130 g per day for women) on 13 days per week; (4) hepatitis C infection; (5) female sex; (6) overweight (body mass index [BMI] of 125 kg/m 2 ); or (7) use of didanosine at time of screening. Exclusion criteria included acute illness, concurrent medications known to affect mitochondria, pancreatitis, or peripheral neuropathy of grade 11. Subjects were randomized at a ratio of 3:2 to reduce the dose of stavudine (from 40 to 20 mg twice daily for subjects weighing у60 kg or from 30 to 15 mg twice daily for subjects weighing !60 kg; "switch arm") or to continue the standard dose ("continuation arm") for 48 weeks. Subjects were asked to continue all other antiretroviral therapy. Stavudine was provided free of charge by Bristol-Myers Squibb. The randomization schedule was prepared by the data manager, who was not linked with patient care. The study was approved by the institutional review boards of both institutions; all subjects provided written informed consent before enrollment.
Study evaluations. After screening, subjects were evaluated at weeks 0 (entry), 4, 12, 24, 36, and 48. At each visit, clinical assessment and laboratory tests (hematology tests, electrolyte measurements, and renal and liver tests) were performed. CD4 cell count and HIV RNA level were measured at weeks 0 and 48. Subjects with confirmed HIV virological failure had their HIV genotype determined. Adherence to study treatments was assessed at every visit by counting dispensed and returned pills. At entry and week 48, PBMCs were collected, and subcutaneous fat was obtained from a 6-mm skin punch biopsy from the upper outer quadrant of the buttocks. The fat samples were separated from the overlying skin and placed in a Ϫ70ЊC freezer until batch processing at the end of the study. At baseline and week 48, fasting pyruvate and lactate measurements were determined at rest and after 10 min of exercise (walking up and down stairs at a fast rate). Fasting was defined as у8 h since oral intake of anything other than water. Venous lactate levels were determined using AIDS Clinical Trials Group guidelines [13] , and levels were determined in real time at each site's laboratory. Fasting lipid levels were measured, and regional body fat, lean body mass, and bone mineral density (BMD) were assessed by whole-body dual-energy x-ray absorptiometry (DEXA) at baseline and week 48. All subjects were consistently scanned using the same machine at each time point. The DEXA scans were calibrated against a common standard and read centrally at Tufts University (Boston, MA). The central reader was blinded to the timing of DEXA and patients' characteristics.
mtDNA assays. The mtDNA assays were performed on batched specimens at the end of the study as described previously [14] . Laboratory personnel were blinded to sample characteristics. Total DNA was extracted with the QIAamp DNA isolation kit (Qiagen). mtDNA and nuclear DNA (nDNA) copy numbers were determined by quantitative PCR using the ABI7700 sequence detection system (Applied Biosystems). The mtDNA ATP6 gene was amplified and quantified with a FAM fluorophore-labeled probe. For nDNA quantification, exon 8 of the GAPDH gene was amplified and quantified using a VIC fluorophore-labeled probe. Amplifications of mitochondrial and nuclear products were performed separately in 96-well optical plates. All samples were run in triplicate. Absolute mtDNA and nDNA copy numbers were calculated using serial dilutions of control plasmids with known mtDNA and nDNA copy numbers.
Subjective assessment of body composition. Questionnaires examining each subject's fat loss and/or accumulation were completed separately by patients and physicians. A lipoatrophy score was calculated on the basis of questions about fat loss in the arms, legs, buttocks, and face. Assessments within each of these sites were rated as 0 for absent, 1 for mild, 2 for moderate, and 3 for severe. Thus, the total lipoatrophy score could vary between 0 and 12. A similar lipohypertrophy score was calculated on the basis of questions about fat gain in the abdomen, neck, and breasts as well as the presence of body lipomas. The total lipohypertrophy score could vary between 0 and 12.
Statistical analysis. Changes in fat and PBMC mtDNA levels were the primary end points on which sample size calculation was based in this study. To account for the levels of mtDNA at baseline, we assessed percentage change in mtDNA levels from entry to week 48. Secondary end points were changes in triglyceride levels; total, non-high-density lipoprotein, and high-density lipoprotein (HDL) cholesterol levels; lactate levels; lactate/pyruvate ratio; DEXA-measured changes in limb fat, lean body mass, and BMD; CD4 cell count; and HIV RNA level. Using a P value of .05, a sample size of 22 was needed to provide 80% power to detect a 50% change from baseline and between arms in fat mtDNA levels. We used Wilcoxon signed rank and Mann-Whitney U tests for within-and between-group differences and Spearman rank correlation for correlations between variables. Linear regression analysis was used to determine possible confounding effects of variables on the end points. We did not adjust P values for multiple comparisons. All analyses were carried out using SAS software, version 8.2 (SAS Institute).
RESULTS
Between November 2004 and December 2005, 26 subjects were screened, and all were randomized. Two subjects withdrew consent before starting the study's treatments, and were excluded from the analysis. Overall, 24 patients (79% of whom were male and 79% of whom were African American; mean age, 36 years) were enrolled (15 in the switch arm); 21 completed the study. Of the 3 subjects who withdrew, 1 subject in the switch arm withdrew at week 4 because of a scheduling conflict; 1 subject in the switch arm died of an overdose of illegal drugs and respiratory failure that was unrelated to study participation at week 37; and 1 subject in the continuation arm withdrew at week 4 because of incarceration. No subject discontinued study treatments because of adverse effects.
Of the 24 subjects in the trial, 21 (88%) were found to have lipoatrophy, and 13 (62%) of these were randomized to the switch arm. The study arms had similar baseline demographic characteristics and laboratory results, except for BMI (higher in the switch arm; ), total lean body mass (higher in P p .003 the switch arm;
), and triglyceride levels (higher in the P p .04 switch arm; ) (table 1) . Only 2 subjects (1 per arm) P p .02 were receiving a stavudine dosage of 30 mg twice daily at study entry (weight, !60 kg). Four others (2 patients per arm) were receiving concomitant didanosine treatment. Four patients in the switch arm and 2 in the continuation arm reported "social alcohol use" at study entry; none reported heavy use. The median baseline CD4 cell count was 558 cells/mm 3 (interquartile range, 207-1698 cells/mm 3 ), and all subjects had an HIV-1 RNA level less than the level of detection (!50 copies/mL at the University Hospitals of Cleveland site; !75 copies/mL at the University of Pennsylvania site) at study entry. The median CD4 cell count did not change between baseline and week 48. However, at 48 weeks, 6 subjects (4 [27%] of 15 in the switch arm vs. 2 [22%] of 9 in the continuation arm) had lost virological control, with a median HIV RNA level of 972 copies/ mL (range, 60-49,400 copies/mL). The genotype could be analyzed for only the 2 subjects with HIV-1 RNA levels of 11000 copies/mL, and no resistance mutations were identified. All 6 subjects reported missing several stavudine treatments, and pill count identified an adherence of !80% of the doses for these 6 subjects, compared with 190% adherence among subjects who maintained virological control.
All subjects maintained other prescribed antiretroviral therapy without change. The median duration of stavudine treatment was 55 months (range, 21-126 months). There were no significant changes in serum creatinine, bilirubin, liver enzyme, or creatinine kinase levels between weeks 0 and 48. None of the subjects, including the 4 with lactate levels of 12.0 mmol/ L at baseline, exhibited symptoms suggestive of mitochondrial toxicity, such as anorexia, weight loss, nausea, vomiting, or abdominal pain. There was no change in alcohol consumption during the study.
Markers of mitochondrial function. Figure 1 illustrates the percentage changes from baseline in fat mtDNA levels. As seen in table 2, at week 48, although there were no significant between-group differences, both median fat mtDNA and lactate levels improved in the switch group (40 copies/cell [range, Ϫ49 to 261 copies/cell; ] and Ϫ0.27 mmol/L [range, Ϫ1.2 P p .02 to 0.25 mmol/L; ], respectively). The percentage change P p .01 from baseline to week 48 in fat mtDNA levels also increased in the switch arm (67%; range, Ϫ34% to 356%;
). No P p .01 changes in levels of fat mtDNA or lactate were seen in the continuation arm. The 4 subjects with lactate levels of 12.0 mmol/L at study entry remained asymptomatic for the study duration and required no discontinuation or change in antiretroviral therapy. Three of the patients (all in the switch arm) finished the study with lactate levels of !2 mmol/L, whereas 1 patient (in the continuation arm) had a lactate level of 2.5 mmol/L at week 48. Fasting pyruvate levels, lactate/pyruvate ratios, and postexercise lactate levels did not change in either arm. PBMC mtDNA levels did not change in either arm. There was no significant correlation between changes in fat mtDNA and changes in PBMC mtDNA or lactate levels in either arm. Also, changes in fat mtDNA and in lactate levels did not correlate with age, sex, limb fat, BMI, use of nonnucleoside reversetranscriptase inhibitors or protease inhibitors, duration of exposure to stavudine, or duration of exposure to thymidine NRTIs. The only significant correlations with changes in fat mtDNA were nadir CD4 cell count ( ; ) and r p 0.94 P p .005 CD4 cell count at baseline ( ; ). r p 0.94 P p .005 Body composition, BMD, and other metabolic parameters. At baseline, the 2 arms were similar with regard to body fat and BMD. There was no significant within-or between-group change in BMI, lipoatrophy scores, patient lipohypertrophy score, limb fat, or trunk fat. There was a modest, statistically significant between-arm difference in the physician-generated lipohypertrophy score (median score for switch arm, Ϫ1 [range, Ϫ3 to 3]; median score for continuation arm, 0 [range, 0-3];
). P p .04 In the continuation arm, a significant loss of BMD was observed at week 48 (median difference, Ϫ1.7%; range, Ϫ6.3% to 0.8%; ), whereas BMD remained stable in the switch P p .02 arm (median difference, 0.0%; range, Ϫ1.2% to 4%;
). P p .37 The between-group difference in the change in BMD was significant (
). There was no association between change P p .003 in BMD and change in lactate or mtDNA measurements from week 0 to 48, regardless of whether analyses included the entire study or the separate arms. There was no correlation between changes in BMD and baseline BMI or changes in BMI. There were no significant between-or within-group differences in change in blood pressure, total cholesterol, HDL cholesterol, triglyceride, or glucose levels.
DISCUSSION
To our knowledge, this is the first randomized, controlled trial to examine a treatment switch to one-half of the standard stavudine dose to alleviate metabolic toxicities in subjects who have virological suppression. Also, our study was the first to examine the effect of stavudine dose reduction on fat mtDNA levels. Our results showed that reducing the stavudine dose by one-half led to an increase in fat mtDNA and a decrease in serum lactate level while preserving HIV virological suppression in subjects who adhered to treatment. A significant loss of BMD was seen in patients receiving standard-dose stavudine, but not in those receiving low-dose stavudine. This change in BMD was not correlated with changes in BMI or body composition.
After 48 weeks of the treatment switch to one-half of the standard dose of stavudine, we found a significant improvement in fat mtDNA and venous lactate levels. This suggests an improvement in mitochondrial function, in contrast to studies in which switching to 30-mg dose of stavudine did not lead to significant changes in mtDNA or lactate levels [12] . However, our study is the first to investigate changes in mtDNA in the adipose tissue with this stavudine dose reduction strategy. The earlier dose reduction study analyzed mtDNA in PBMCs [12] . Mitochondrial toxicity is tissue specific; thus far, conflicting results have emerged from the investigations of PBMC mtDNA [9, [15] [16] [17] . These conflicting results may be secondary to platelet contamination [18] or to the specific antiretroviral therapy used [17] . In contrast, several groups have consistently found fat mtDNA depletion in NRTI-treated subjects [4, 9, 19, 20] . This outlines the importance of assessing mtDNA levels in fat and not only in PBMCs. Improvements in fat mtDNA levels did not correlate with adherence to antiretroviral therapy or with changes in HIV RNA levels.
Surprisingly, despite the significant improvement in mitochondrial function, no changes were seen in subjective or objective measurements of body composition. The majority of our subjects had lipoatrophy at baseline, and results were unchanged when we excluded the 3 subjects without lipoatrophy (results not shown). Although one could argue that recovery of limb fat is slow to occur, other studies in which stavudine treatment was switched to nonthymidine NRTIs were able to show a modest but significant change in limb fat after 48 weeks of the change in treatment [6] [7] [8] .
At baseline, the switch arm had elevated BMI and lean body mass and a trend toward elevated limb fat, compared with those measurements in the continuation arm. In some of the prior antiretroviral therapy switch studies, baseline BMI was significantly and positively associated with change in limb fat [7] ; the slight difference in baseline limb fat in our study may have confounded the results. However, we found no correlation between changes in limb fat (absolute or percentage change) and baseline BMI or changes in BMI.
There was a remarkable variability in the observed changes in limb fat in both arms, but there were no clear outliers. This wide variability had been noted in other antiretroviral therapy switch studies. In TARHEEL (Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy), leg fat changes after a stavudine-to-abacavir switch increased a median of 15% (range, Ϫ53% to 206%) [6] . Arm fat had similar variability, with a median increase of 38% (range, Ϫ37% to 174%). In the MITOX (mitochondrial toxicity) study, no ranges were reported, but the mean ‫ע‬ SD increase in limb fat at week 104 was kg [7] . Thus, 1.26 ‫ע‬ 2.02 there is a consistent wide variability in the limb fat responses to antiretroviral therapy switch strategies.
The effect of switching to low-dose stavudine on fat mtDNA was less than that previously reported with stavudine discontinuation [9] . Compared with the TARHEEL study ( ), n p 16 which observed an increase of 122% in fat mtDNA 48 weeks after discontinuation of stavudine [9] , our study found a smaller change associated with the switch to low-dose stavudine (median increase, 67% at 48 weeks). The lack of body composition changes found in this study cannot be explained by variation in the study population, because age, stavudine duration, and other characteristics were similar in both studies. Thus, although improvement in mitochondrial function is observed with low-dose stavudine in this study, it remains suboptimal compared with other strategies, such as substitution of nonthymidine NRTIs for stavudine. This may also explain the lack of improvement in limb fat in this study. The apparent protection provided by low-dose stavudine against the decrease in BMD seen over the 48 weeks of the study in the control arm is surprising given that the effect of NRTI doses on BMD has not been previously investigated. This is somewhat consistent with another study, in which patients receiving stavudine or zidovudine therapy had a small but significant decrement in BMD over the 104-week observation period, whereas the BMD for those who switched to abacavir remained stable [7] . A mitochondrial etiology of decreased BMD in HIV infection could indeed explain these findings. Thymidine analogues may affect bone metabolism indirectly through their effect on mitochondria, which may be important in the development of reduced BMD [21] . A large, cross-sectional study of HIV-infected men showed that an independent predictor of osteopenia is the presence of lactic acidosis [22] , which may decrease bone formation and increase bone resorption [23] . Additional studies are required to test this potential association.
The significant positive correlation found between fat mtDNA and CD4 cell count is consistent with the observation that advanced HIV disease is independently associated with lipoatrophy [24] . In addition, lower CD4 cell count is predictive of hyperlactatemia and lactic acidosis [25] . Thus, the correlation we found between CD4 cell count and fat mtDNA further strengthens the suggestion that advanced HIV infection is associated with higher risk of mitochondrial toxicity from antiretroviral therapy. With limited resources for HIV treatment in developing countries, low-cost treatment options such as stavudine still need to be pursued if safety can be improved by dose optimization. However, caution should be exercised with regard to the extent to which it would be safe to lower the dose (15-30 mg), because this low-dose strategy may be less tolerant to breaches in treatment adherence.
Despite the limitations of the small sample size and the openlabel nature, this study provides valuable information as to the role of low-dose stavudine in amelioration of metabolic parameters. The results suggest that the switch to one-half of the standard dose of stavudine modestly but significantly improved mitochondrial indices without changes in body composition. The switch was able to mitigate the loss of BMD seen over time with standard-dose stavudine. Finally, low-dose stavudine was not associated with loss of virological control. For either of the stavudine doses, subjects with low adherence to therapy exhibited higher risk of virological failure.
